Dr Erin Gainer is a global leader and biopharma strategist in women’s health and rare diseases, having led multiple drug development programs and served as CEO and then Chair of the Board of HRA Pharma, culminating in a trade sale in 2022. She is passionate about driving innovation to respond to unmet medical needs and is the author/inventor of dozens of peer-reviewed publications and patents. She currently advises life sciences companies and investors, serves as an independent director for public and private companies, and aims to accelerate innovation as a business angel and impact investor. A graduate from Rice University and John Hopkins School of Public Health, Erin has a PhD in epidemiology from Paris-Sud University and a Global Executive MBA from INSEAD.